Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28319363 | 0.81 | TDP1 (0.42) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL28294144 | 0.80 | HTR2A (0.44) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL27975969 | 0.80 | TDP1 (0.41) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL27406049 | 0.79 | HTR2A (0.47) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL16706320 | 0.78 | GAA (0.38) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL28837500 | 0.78 | GPR35 (0.42) | GAATDP1KMT2AHTTMEN1 | |
| SCHEMBL15077831 | 0.77 | KMT2A (0.39) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL23152886 | 0.77 | HTR2A (0.43) | GAAHTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL1715998 | 0.76 | GAA (0.44) | GAATDP1KMT2AHTTTSHR | |
| SCHEMBL2850765 | 0.75 | NOTUM (0.43) | TDP1KMT2AHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109180554-A | A kind of method of methylation reaction | 广东石油化工学院 | 2019-01-11 | — | — | CN | disclosed |
| CN-102503881-B | Optically active tryptamine derivative and synthetic method and application thereof | UNIV EAST CHINA NORMAL | 2013-08-07 | — | — | CN | disclosed |
| CN-102617443-A | Optically active indole derivative, synthetic method and application thereof | UNIV EAST CHINA NORMAL | 2012-08-01 | — | — | CN | disclosed |
| CN-102503881-A | Optically active tryptamine derivative and synthetic method and application thereof | UNIV EAST CHINA NORMAL | 2012-06-20 | — | — | CN | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| CN-1823063-B | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD | 2010-07-14 | — | — | CN | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| CN-1823063-A | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| EP-1633748-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| CN-1194966-C | Methylation of indole compounds using dimethyl carbonate | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| CN-1425003-A | Methylation of indole compounds from dimethyl carbonate | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | GAA 477/4885HTR2A 1422/4885HTR2C 1379/4885 |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | GAA 477/4885HTR2A 1422/4885HTR2C 1379/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | GAA 477/4885HTR2A 1422/4885HTR2C 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.